Holen Sie sich die Stockscreener-App
32.75
0.27%
-0.09
Handel nachbörslich:
33.50
0.75
+2.29%
Schlusskurs vom Vortag:
$32.84
Offen:
$33
24-Stunden-Volumen:
456.17K
Relative Volume:
1.07
Marktkapitalisierung:
$1.80B
Einnahmen:
$345.60M
Nettoeinkommen (Verlust:
$-79.01M
KGV:
-20.41
EPS:
-1.6045
Netto-Cashflow:
$-18.62M
1W Leistung:
+2.31%
1M Leistung:
-15.27%
6M Leistung:
+9.83%
1J Leistung:
-5.89%
1-Tages-Spanne:
$32.49
$33.95
1-Wochen-Bereich:
$30.76
$33.95
52-Wochen-Spanne:
$23.15
$41.54
Immunocore Holdings Plc Adr Stock (IMCR) Company Profile
Firmenname
Immunocore Holdings Plc Adr
Sektor
Branche
Telefon
01235 5430281
Adresse
90 PARK DRIVE, OXFORDSHIRE
Vergleichen Sie IMCR mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
IMCR
Immunocore Holdings Plc Adr
|
32.75 | 1.80B | 345.60M | -79.01M | -18.62M | -1.6045 |
|
VRTX
Vertex Pharmaceuticals Inc
|
457.03 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
547.74 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
329.77 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
545.11 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
244.32 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Immunocore Holdings Plc Adr Stock (IMCR) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-05-27 | Eingeleitet | Deutsche Bank | Buy |
| 2024-12-13 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2024-11-11 | Herabstufung | Mizuho | Outperform → Neutral |
| 2024-10-24 | Eingeleitet | UBS | Sell |
| 2024-10-07 | Herabstufung | Guggenheim | Buy → Neutral |
| 2024-04-29 | Eingeleitet | Leerink Partners | Outperform |
| 2023-11-20 | Fortgesetzt | JP Morgan | Overweight |
| 2023-11-02 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2023-10-31 | Eingeleitet | Robert W. Baird | Outperform |
| 2023-09-13 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2023-09-13 | Eingeleitet | Needham | Buy |
| 2023-08-16 | Eingeleitet | CapitalOne | Overweight |
| 2023-07-17 | Eingeleitet | Canaccord Genuity | Hold |
| 2023-03-31 | Eingeleitet | Mizuho | Buy |
| 2023-03-30 | Eingeleitet | Guggenheim | Buy |
| 2023-03-24 | Eingeleitet | Bryan Garnier | Buy |
| 2022-12-16 | Hochstufung | Goldman | Neutral → Buy |
| 2022-11-30 | Eingeleitet | Barclays | Overweight |
| 2022-09-09 | Eingeleitet | Morgan Stanley | Overweight |
| 2022-09-08 | Eingeleitet | Ladenburg Thalmann | Buy |
| 2022-08-08 | Eingeleitet | Cowen | Outperform |
| 2022-08-02 | Eingeleitet | BTIG Research | Buy |
| 2022-02-08 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-10-20 | Eingeleitet | Oppenheimer | Outperform |
| 2021-03-02 | Eingeleitet | Goldman | Neutral |
| 2021-03-02 | Eingeleitet | JP Morgan | Overweight |
| 2021-03-02 | Eingeleitet | Jefferies | Buy |
Alle ansehen
Immunocore Holdings Plc Adr Aktie (IMCR) Neueste Nachrichten
Immunocore’s SWOT analysis: stock outlook amid pipeline progress, market challenges By Investing.com - Investing.com South Africa
Immunocore’s SWOT analysis: stock outlook amid pipeline progress, market challenges - Investing.com India
Immunocore at Jefferies Global Healthcare Conference: Strong Growth and Promising Trials - Investing.com India
Wall Street Analysts Think Immunocore (IMCR) Could Surge 65.22%: Read This Before Placing a Bet - sharewise
Deutsche Bank sets $65 target on Immunocore stock, rates Buy - Investing.com
Deutsche Bank sets $65 target on Immunocore stock, rates Buy By Investing.com - Investing.com India
Immunocore’s SWOT analysis: biotech firm’s stock faces challenges amid growth - Investing.com India
Is it a Good Idea to Invest in Immunocore Stock Right Now? - MSN
Wall Street Analysts See an 114.35% Upside in Immunocore (IMCR): Can the Stock Really Move This High? - MSN
Balance Sheet Dive: Hippo Holdings Inc (HIPO)’s Debt-to-Equity and Long-Term Debt/Eq Ratios - DWinneX
Analyzing Ratios: Symbotic Inc (SYM)’s Financial Story Unveiled - DWinneX
New Strong Buy Stocks for May 8th - The Globe and Mail
Immunocore stock rises as Q1 results top estimates By Investing.com - Investing.com South Africa
Immunocore stock rises as Q1 results top estimates - Investing.com
Immunocore Holdings earnings beat by $0.49, revenue topped estimates - Investing.com
Compared to Estimates, Immunocore (IMCR) Q1 Earnings: A Look at Key Metrics - Yahoo Finance
ESPR's Q1 Earnings Miss Estimates, Revenues Beat, Stock Down - Barchart.com
AXSM Q1 Loss Narrower Than Expected, Auvelity Drives Revenues Y/Y - The Globe and Mail
Agios' Q1 Loss Narrower Than Expected, Revenues Lag Estimates - Barchart.com
Repligen's Q1 Earnings Beat Estimates, Revenues Surge Y/Y - Barchart.com
Wall Street Analysts Think Immunocore (IMCR) Could Surge 107.45%: Read This Before Placing a Bet - Yahoo Finance
Mizuho cuts Immunocore stock price target to $33 from $38 - Investing.com
Immunocore stock hits 52-week low at $27.19 amid market challenges By Investing.com - Investing.com South Africa
Immunocore stock hits 52-week low at $27.19 amid market challenges - Investing.com
Do investors need to be concerned about Immunocore Holdings plc ADR (IMCR)? - US Post News
Immunocore (IMCR) Moves 6.0% Higher: Will This Strength Last? - MSN
Immunocore holdings sees $23.99 million in stock purchases by Baker Bros - Investing.com South Africa
Immunocore amends senior notes indenture, files prospectus - Investing.com India
Immunocore amends senior notes indenture, files prospectus By Investing.com - Investing.com South Africa
H.C. Wainwright maintains $100 target on Immunocore stock - Investing.com
Immunocore’s SWOT analysis: biotech firm’s stock outlook amid HIV and cancer drug progress - Investing.com
BTIG maintains Immunocore stock Buy rating, $91 target - Investing.com
Immunocore stock hits 52-week low at $27.59 amid market challenges - Investing.com
Immunocore reports promising HIV trial results By Investing.com - Investing.com South Africa
Immunocore reports promising HIV trial results - Investing.com India
Immunocore presents initial multiple ascending dose data for HIV functional cure candidate in an oral presentation at CROI 2025 - GlobeNewswire Inc.
Immunocore at TD Cowen Conference: Strategic Growth and Innovation - Investing.com India
Immunocore at TD Cowen Conference: Strategic Growth and Innovation By Investing.com - Investing.com South Africa
PBYI Stock Rises as Q4 Earnings & Sales Outpace EstimatesFebruary 28, 2025 - Zacks Investment Research
Earnings call transcript: Immunocore Holdings Q4 2024 misses EPS - Investing.com
Finanzdaten der Immunocore Holdings Plc Adr-Aktie (IMCR)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.45%
0.86%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):